Drug trial aims to shrink tumors before surgery, hoping to avoid recurrence
NCT ID NCT04323202
Summary
This small, early-stage study tested if giving the immunotherapy drug pembrolizumab before surgery could help treat a serious form of skin cancer called basal cell carcinoma on the head and neck. The goal was to see if the drug could shrink the tumors, make surgery more effective, and lower the chance of the cancer coming back. Researchers also monitored the safety of this approach and studied how the patients' immune systems responded to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.